-
[MAH] Chinese original medicine bid farewell to the era of selling young crops
Time of Update: 2017-01-16
On January 12, the State Food and Drug Administration (CFDA) issued a notice approving the listing of domestic generic drugs, such as gefitinib tablets produced by Qilu Pharmaceutical (Hainan) Co., Lt
-
CFDA approved the listing of generic drugs such as anti AIDS drug efaviron tablets
Time of Update: 2017-01-14
Recently, the State Food and Drug Administration approved the listing of domestic generic drugs of gefitinib, eferene and tenofovir fumarate dipivoxil Gefitinib, a tyrosine kinase inhibitor of epiderm
-
Shanghai Fuxing Pharmaceutical "kafezomi" has been approved for clinical research and development, with an investment of more than 10 million yuan
Time of Update: 2017-01-14
1 overview recently, Chongqing pharmaceutical industry Research Institute Co., Ltd., a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (hereinafter referred to as "the company"),
-
Materials and tablets of cytarabine hydrochloride valine ester, a new chemical drug of Shenyang Pharmaceutical University, obtained clinical approval
Time of Update: 2017-01-07
Recently, the raw materials and tablets (acceptance No.: cxhl1502498, cxhl1502499 and cxhl1502500) of the new chemical drug cytarabine hydrochloride valine ester, developed by Shenyang Pharmaceutical
-
The first class of new drug uropolypeptide injection of tailing medicine was approved for marketing
Time of Update: 2017-01-07
The national class 1.1 new drug, xitique (niacin injection), developed by thaling biopharmaceutical Jiangsu Co., Ltd., a subsidiary of thaling pharmaceutical, has been approved by the State Food and D
-
Sansheng pharmaceutical: new gout drug sss11 obtained CFDA clinical trial application approval
Time of Update: 2017-01-07
Recently, Sansheng pharmaceutical announced that its new product, pegylated recombinant uric acid oxidase pegsiticase (sss11), has obtained the approval document for clinical trials of new drugs issue
-
China's patents for the three heavyweight drugs will expire in 2017. How is the "preparation" progress of local pharmaceutical companies?
Time of Update: 2017-01-05
According to statistics, in 2017, there are nearly 20 nce (new molecular entity) new drugs whose compound patents are about to expire in China, among which there are 3 heavyweight products with annual
-
[year end inventory] application for class 1 new drugs of domestic chemicals in 2016
Time of Update: 2016-12-31
The year-end message is coming to the end of 2016 In this year, various policies such as "new drug rapid review and approval system", "clinical data specification", "generic drug consistency evaluatio
-
A new drug to cure hepatitis C will be on the market! The first local DAA drug breakthrough
Time of Update: 2016-12-28
On December 27, Geli pharmaceutical announced that the company's first application for listing the original innovative hepatitis C drug danorevir (asc08) has passed the comprehensive on-site inspectio
-
Tianshili: release the results of phase III clinical trial of Compound Danshen Dropping Pills in FDA international multi center
Time of Update: 2016-12-24
Recently, compound Danshen dropping pill, the exclusive product of Tianshili Pharmaceutical Group Co., Ltd which has been listed in China, is a global multi center randomized double blind large sample
-
CFDA approved snerry ® for combination therapy of MDR-TB in adults
Time of Update: 2016-12-05
On December 1, 2016, Xi'an Janssen Pharmaceutical Co., Ltd announced that China's State Food and drug administration has approved snerry ® (betaquiline fumarate tablets) as a part of the combined trea
-
College students develop new cancer drugs
Time of Update: 2016-12-03
Recently, at the closing ceremony of the second Dongguan University Students' science and Technology Innovation Festival, the university students' team of Guangdong Medical University, after two years
-
Pharmaceutical companies take the wrong path: relying on practical research and development to counter attack the successful Yabang pharmaceutical industry
Time of Update: 2016-12-02
On November 16, the 80th anniversary of China Pharmaceutical University, Yabang pharmaceutical signed a contract with the university to build a joint research and Development Center for new pharmaceut
-
Southeast University and bringer Ingelheim: jointly develop a new therapy for hearing impairment
Time of Update: 2016-11-29
On November 28, bringer Ingelheim and the Institute of life sciences of Southeast University of China jointly announced the launch of a joint research project to develop a new type of therapy for hear
-
New breakthrough in drug target research of Zika virus by Chinese scientists
Time of Update: 2016-11-23
The research team, led by Professor Yang Haitao of Tianjin University and Professor Zhu Xiaoyun of Nanjing University, recently made an important breakthrough in revealing the key drug targets of Zika
-
Hengrui medicine vonolazan fumarate preparation approved for clinical use
Time of Update: 2016-11-21
On November 19, Jiangsu Hengrui Pharmaceutical Co., Ltd officially announced that its subsidiaries Chengdu Shengdi Pharmaceutical Co., Ltd and Chengdu Xinyue Pharmaceutical Co., Ltd recently received
-
Gao Yan, vice chairman of Bishengyuan: forge ahead in the field of health
Time of Update: 2016-11-18
A successful enterprise should not only have the courage to stand up for the tide and dare to compete, but also have the courage to take on the people-oriented gentleness and courage, as is the case w
-
Pfizer children's pneumococcal vaccine approved in China
Time of Update: 2016-11-03
Pfizer yesterday announced that China's State Food and drug administration has officially approved the use of its Prevenar 13 vaccine to help prevent pneumococcal infection in infants and children bet
-
The anti-inflammatory drug Humira (adamumumab) of ibuprofen was approved by Japan for the treatment of noninfectious uveitis
Time of Update: 2016-10-26
Humira, the flagship product of American biotechnology giant abbvie, received good news in the US and EU regulation at the same time in July this year In the United States, the FDA approved Humira for
-
FDA grants Bristol Meyer PD-1 immunotherapy opdivo a priority qualification for the treatment of advanced urothelial cancer
Time of Update: 2016-10-26
The tumor immunotherapy giant BMS PD-1 immunotherapy opdivo recently received a good news in the US regulatory field The US Food and Drug Administration (FDA) has accepted the supplementary biological
